Evidence map›Paper›PMID 36052368›Full record

ArticlebioRxiv : the preprint server for biology2022

Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain.

Leerang Yang, Matthew Van Beek, Zijun Wang, Frauke Muecksch, Marie Canis, Theodora Hatziioannou, Paul D Bieniasz, Michel C Nussenzweig, Arup K Chakraborty

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Leerang YangDepartments of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Matthew Van BeekDepartments of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Zijun WangLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Frauke MueckschLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Marie CanisLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Arup K ChakrabortyDepartments of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
Rockefeller University · USHoward Hughes Medical Institute · USMassachusetts Institute of Technology · USRagon Institute of MGH, MIT and Harvard · US

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Class Switch Recombination in B LymphocytesR37AI037526 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$5.4M
SIGNALLING PATHWAYS IN AUTOIMMUNITYR01AI037526 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 1994 to 2012
$5.0M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI037526NIAID NIH HHS R37 AI037526NIAID NIH HHS U19 AI057229
6 · The paper itself

Abstract

The Omicron variant of SARS-CoV-2 evades neutralization by most serum antibodies elicited by two doses of mRNA vaccines, but a third dose of the same vaccine increases anti-Omicron neutralizing antibodies. By combining computational modeling with data from vaccinated humans we reveal mechanisms underlying this observation. After the first dose, limited antigen availability in germinal centers results in a response dominated by B cells with high germline affinities for immunodominant epitopes that are significantly mutated in an Omicron-like variant. After the second dose, expansion of these memory cells and differentiation into plasma cells shape antibody responses that are thus ineffective for such variants. However, in secondary germinal centers, pre-existing higher affinity antibodies mediate enhanced antigen presentation and they can also partially mask dominant epitopes. These effects generate memory B cells that target subdominant epitopes that are less mutated in Omicron. The third dose expands these cells and boosts anti-variant neutralizing antibodies.

Identifiers

PMID36052368
PMCPMC9435403
OpenAlexW4293248699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.